A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Fiche publication
Date publication
mars 2023
Journal
Gynecologic oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KURTZ Jean-Emmanuel, Dr KAMINSKY Marie-Christine
Tous les auteurs :
Blanc-Durand F, Yaniz-Galende E, Llop-Guevara A, Genestie C, Serra V, Herencia-Ropero A, Klein C, Berton D, Lortholary A, Dohollou N, Desauw C, Fabbro M, Malaurie E, Bonichon-Lamaichhane N, Dubot C, Kurtz JE, de Rauglaudre G, Raban N, Chevalier-Place A, Ferron G, Kaminsky MC, Kramer C, Rouleau E, Leary A
Lien Pubmed
Résumé
Homologous recombination deficiency (HRD), defined as BRCA1/2 mutation (BRCAmut) or high genomic instability, is used to identify ovarian cancer (OC) patients most likely to benefit from PARP inhibitors. While these tests are useful, they are imperfect. Another approach is to measure the capacity of tumor cells to form RAD51 foci in the presence of DNA damage using an immunofluorescence assay (IF). We aimed to describe for the first time this assay in OC and correlate it to platinum response and BRCAmut.
Mots clés
BRCA, Homologous recombination, Neoadjuvant chemotherapy, Ovarian cancer, RAD51
Référence
Gynecol Oncol. 2023 03 1;171:106-113